Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Tesla expected to post double-digit declines in earnings, sales. Fed chief Powell speech in focus as central bank ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Wall Street analysts predict lower second-quarter profits for Ford, GM and Stellantis due to tariff pressures and slowing sales.

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

The Q2 earnings reporting cycle is underway with the peak of the season still to come. It will begin mid-July with the report from JPMorgan Chase & Company (NYSE: JPM), making now a good time to ...

Everything to Know about Macro and Markets The S&P 500 (SPX) and the Nasdaq-100 (NDX) inched down from Thursday’s record highs, though still ...

The expectation is for Q2 earnings to increase by +5% from the same period last year on +4% higher revenues. This will be a material deceleration from the growth trend of recent quarters and will ...

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.